-
Access to HealthcareCardiovascular DiseaseHeart DiseaseNovartis Access
-
Basel, March 18, 2020 — Novartis announced today the publication of three pivotal Phase III clinical trials for inclisiran, a potential first-in-class small interfering RNA (siRNA) investigational agent for hyperlipidemia in adults. The findings were published in two online articles ahead of print in The New England Journal of Medicine. The…Reimagine MedicineHeart DiseaseCardiovascular Disease